Natera, Inc. (NTRA) — AI 주식 분석

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

Natera, Inc.(NTRA)는 미국 거래소에 상장되어 있으며, 최근 주가는 $271.39, 시가총액은 $38.9B입니다. 성장 잠재력, 재무 건전성, 모멘텀에서 35/100(신중)으로 평가됩니다.

Natera, Inc. is a diagnostics company specializing in molecular testing services, including non-invasive prenatal testing and cancer screening. Their 혁신적인 technologies and 전략적 파트너십 position them for growth in the expanding genetic testing market.

주요 정보: 가격: $271.39 일일 변동: +0.58% 시가총액: $38.9B 애널리스트 목표가: $270.00 목표가 상승여력: -0.5% AI 점수: 35/100 거래소: NASDAQ

기업 개요

요약:

Natera, Inc. develops and commercializes molecular testing services, including prenatal and cancer screening, leveraging proprietary technology and 전략적 파트너십. With a focus on non-invasive methods and personalized medicine, Natera addresses a growing market for genetic information, while facing competition and 규제 hurdles in the healthcare sector.

NTRA는 무엇을 하는 회사인가요?

Founded in 2003 and based in Austin, Texas, Natera, Inc. has evolved into a leading diagnostics company focused on molecular testing services. Originally named Gene Security Network, Inc., the company rebranded to Natera, Inc. in 2012 to reflect its expanded focus. Natera's core offerings include Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a maternal blood sample. This test also extends to twin pregnancies, deter광업 zygosity. Other key products include Vistara, a single-gene mutation screening test; Horizon carrier screening, which identifies carrier status for various genetic diseases; and Spectrum, used during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Natera also provides Anora miscarriage testing to analyze fetal chromosomes and non-invasive paternity testing. The company's Constellation 소프트웨어 플랫폼 allows laboratory 고객 to access Natera's algorithms and bioinformatics. Signatera, a circulating tumor DNA (ctDNA) technology, screens for mutations independent of an individual's tumor, while Prospera assesses organ transplant rejection. Natera markets its products through a direct sales force and a network of laboratory and distribution partners. 전략적 파트너십 with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance Natera's capabilities in NGS-based genetic testing and personalized ctDNA monitoring.

NTRA의 투자 테제는 무엇인가요?

Natera's 투자 논거 hinges on the increasing demand for non-invasive genetic testing and personalized medicine. The company's strong 매출총이익률 of 65.2% indicates 가격 결정력 and efficient operations. Growth catalysts include expanding applications for Signatera in cancer monitoring and Prospera in transplant rejection assessment. However, the company's negative 순이익률 of -9.0% raises concerns about 수익성. Key value drivers include 전략적 파트너십 and continued 혁신 in molecular diagnostics. Potential risks include competition from established players like IQVIA Holdings Inc. and evolving 규제 landscapes in the diagnostics industry. 투자자 should monitor Natera's ability to achieve 수익성 while sustaining 매출 성장 in the long term.

NTRA는 어떤 산업에서 운영되고 있나요?

Natera operates in the rapidly evolving medical diagnostics and research industry. The market for genetic testing is expanding due to technological advancements, increasing awareness of personalized medicine, and growing demand for early disease detection. Key trends include non-invasive testing, liquid biopsies, and the use of 인공지능(AI) in diagnostics. Natera competes with established players like IQVIA Holdings Inc. and Koninklijke Philips N.V., as well as specialized diagnostics companies. The industry is subject to 규제 oversight and reimbursement policies, which can impact market access and adoption of new technologies. Natera's focus on 혁신 and 전략적 파트너십 positions it to capitalize on the 성장 기회 in this dynamic market.

Medical - Diagnostics & Research

헬스케어

NTRA의 성장 기회는 무엇인가요?

Expansion of Signatera into broader oncology applications: Signatera, Natera's circulating tumor DNA technology, has 상당한 potential for growth in cancer monitoring and personalized treatment. The market for ctDNA-based diagnostics is projected to reach billions of dollars as it enables early detection of recurrence and treatment response monitoring. Natera's 진행 중인 임상시험 and 파트너십 with oncology centers will drive adoption of Signatera, offering a 경쟁 우위 in the personalized cancer care market. Timeline: 진행 중인.
Increased adoption of Prospera in transplant rejection assessment: Prospera offers a non-invasive method to assess organ transplant rejection, reducing the need for invasive biopsies. The market for transplant diagnostics is growing due to the increasing number of organ transplants performed annually. Natera's focus on clinical validation and 파트너십 with transplant centers will drive adoption of Prospera, positioning it as a leading solution in transplant monitoring. Timeline: 진행 중인.
Geographic expansion into international markets: Natera has the opportunity to expand its presence in international markets, particularly in Europe and Asia, where demand for genetic testing is growing. 전략적 파트너십 with local distributors and laboratories can facilitate market entry and accelerate adoption of Natera's products. The 글로벌 시장 for prenatal and cancer screening is substantial, offering 상당한 성장 잠재력 for Natera. Timeline: 2-3 years.
Development of new diagnostic tests for other diseases: Natera's proprietary 기술 플랫폼 can be 레버리지d to develop new diagnostic tests for other diseases, such as cardiovascular disease and neurodegenerative disorders. Expanding into new therapeutic areas will diversify Natera's product portfolio and reduce its reliance on prenatal and cancer screening. The market for these diagnostic tests is substantial, offering 상당한 성장 잠재력. Timeline: 3-5 years.
Leveraging Constellation 플랫폼 for broader 고객 기반: The Constellation cloud-based 소프트웨어 플랫폼 allows laboratory 고객 to access Natera's algorithms and bioinformatics, enabling them to validate and launch their own tests. Expanding the 고객 기반 for Constellation will generate recurring 매출 and strengthen Natera's position as a technology provider in the diagnostics industry. The market for bioinformatics solutions is growing, driven by the increasing complexity of genomic data. Timeline: 진행 중인.

시가총액 of $30.42 billion reflects 투자자 confidence in Natera's 성장 잠재력 in the diagnostics market.
매출총이익률 of 65.2% indicates strong 가격 결정력 and efficient cost 경영진 in molecular testing services.
베타 of 1.68 suggests higher 변동성 compared to the market, potentially offering greater returns but also increased risk.
파트너십 with BGI Genomics Co., Ltd. expands Natera's reach in NGS-based genetic testing assays.
Signatera's application in circulating tumor DNA monitoring presents a 상당한 growth opportunity in personalized cancer treatment.

NTRA는 어떤 제품과 서비스를 제공하나요?

Develop and commercialize non-invasive prenatal tests (NIPT) to screen for fetal chromosomal abnormalities.
Offer single-gene mutation screening tests to identify genetic disorders.
Provide carrier screening services to determine carrier status for various genetic diseases.
Offer testing services for in vitro fertilization (IVF) cycles to identify chromosomal anomalies.
Provide miscarriage testing products to analyze fetal chromosomes.
Offer non-invasive paternity testing services.
Provide circulating tumor DNA (ctDNA) technology for cancer monitoring.
Offer testing services to assess organ transplant rejection.

NTRA는 어떻게 수익을 창출하나요?

Direct sales of molecular testing services to healthcare providers and patients.
파트너십 with laboratories and distribution partners to expand market reach.
Licensing of proprietary technology and algorithms to other companies.
Recurring 매출 from 소프트웨어 플랫폼 (Constellation) 구독s.

Obstetricians and gynecologists who order prenatal tests for their patients.
Oncologists who use ctDNA testing to monitor cancer patients.
Transplant centers that use Prospera to assess organ transplant rejection.
Infertility clinics that use Spectrum during IVF cycles.
Laboratories that use Constellation to develop and validate their own tests.

Proprietary 기술 플랫폼 for molecular testing.
Extensive database of genomic data.
Strong brand reputation in prenatal and cancer screening.
전략적 파트너십 with leading healthcare providers and research institutions.

NTRA 주가를 상승시킬 수 있는 요인은 무엇인가요?

예정된: Publication of clinical trial results for Signatera in various cancer types.
진행 중인: Expansion of commercial 파트너십 for Prospera in transplant centers.
진행 중인: 규제 approvals for new diagnostic tests in international markets.
예정된: Launch of new features and capabilities for the Constellation 플랫폼.

NTRA의 주요 리스크는 무엇인가요?

Potential: Increased competition from established players in the diagnostics industry.
Potential: Evolving 규제 landscape for genetic testing could impact market access.
진행 중인: Reimbursement pressures from healthcare payers could limit adoption of new tests.
Potential: Technological obsolescence could render existing products less competitive.
진행 중인: Negative 순이익률 poses a risk to 장기 financial sustainability.

NTRA의 핵심 강점은 무엇인가요?

Proprietary 기술 플랫폼 for non-invasive genetic testing.
Strong brand reputation in prenatal and cancer screening.
Extensive network of laboratory and distribution partners.
Growing adoption of Signatera in cancer monitoring.

NTRA의 약점은 무엇인가요?

Negative 순이익률 raises concerns about 수익성.
Reliance on a limited number of key products.
Exposure to 규제 리스크s and reimbursement challenges.
High 베타 indicates higher 변동성 compared to the market.

NTRA에게 어떤 기회가 있나요?

Expansion of Signatera into broader oncology applications.
Increased adoption of Prospera in transplant rejection assessment.
Geographic expansion into international markets.
Development of new diagnostic tests for other diseases.

NTRA는 어떤 위협에 직면하고 있나요?

Competition from established players in the diagnostics industry.
Evolving 규제 landscape for genetic testing.
Reimbursement pressures from healthcare payers.
Potential for technological obsolescence.

NTRA의 경쟁사는 누구인가요?

Teva 제약 Industries Limited — Focuses on generic and specialty medicines, competing indirectly in diagnostics. — (TEVA)
IQVIA Holdings Inc. — Provides clinical research and data analytics, overlapping in some diagnostic areas. — (IQV)
Koninklijke Philips N.V. — Offers medical imaging and patient monitoring solutions, competing in healthcare technology. — (PHG)
Mettler-Toledo International Inc. — Provides laboratory instruments and services, competing in 연구개발(R&D) tools. — (MTD)
BioNTech SE — Focuses on mRNA-based therapies and vaccines, potentially overlapping in personalized medicine. — (BNTX)

목표 주가

Analyst Consensus Target: $270.00
Current price: $203.19
Implied Upside: +32.9%

회사 프로필

CEO: Steven Leonard Chapman
Headquarters: Austin, CA, US
Employees: 4,424
Founded: 2015

AI 인사이트

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based 소프트웨어 product that enables laboratory 고객 to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a 파트너십 agreement with BGI Genomics Co., Ltd.

질문 및 답변

What does Natera, Inc. do?

Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services, with a focus on non-invasive prenatal testing (NIPT) and cancer screening. The company's key products include Panorama, Signatera, and Prospera, which address the growing demand for genetic information in reproductive health and oncology. Natera's 비즈니스 모델 involves direct sales to healthcare providers and patients, as well as 파트너십 with laboratories and distribution partners. The company's proprietary 기술 플랫폼 and extensive database of genomic data provide a 경쟁 우위 in the rapidly evolving diagnostics market.

What do analysts say about NTRA stock?

Analyst 컨센서스 on NTRA stock is generally positive, reflecting optimism about the company's growth prospects in the diagnostics market. Key 밸류에이션 metrics include 주가매출비율(PSR) and enterprise value-to-매출 multiple, which are used to assess Natera's 밸류에이션 relative to its peers. Growth considerations include the expansion of Signatera into broader oncology applications and the increased adoption of Prospera in transplant rejection assessment. However, analysts also note the risks associated with competition, 규제 변화, and reimbursement pressures. 투자자 should conduct their own due diligence and consider their risk tolerance before investing in NTRA stock.

What are the main risks for NTRA?

The main risks for Natera, Inc. include competition from established players in the diagnostics industry, evolving 규제 landscape for genetic testing, and reimbursement pressures from healthcare payers. Increased competition could lead to price erosion and loss of 시장점유율. Changes in regulations could impact the market access and adoption of Natera's products. Reimbursement pressures could limit the willingness of healthcare providers and patients to pay for Natera's tests. Additionally, technological obsolescence poses a risk to Natera's 장기 competitiveness. The company's negative 순이익률 also raises concerns about its financial sustainability.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.